Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UTI Drugs Market

ID: MRFR/Pharma/66269-HCR
200 Pages
Satyendra Maurya
Last Updated: March 28, 2026

UTI Drugs Market Research Report: Size, Share, Trend Analysis By Drug Type Outlook (Antibiotics, Antiseptics, Analgesics, Antifungals) By Indication Outlook (Uncomplicated Urinary Tract Infection, Complicated Urinary Tract Infection, Recurrent Urinary Tract Infection) By Administration Route Outlook (Oral, Intravenous, Topical, Intramuscular) By Patient Demographics Outlook (Adults, Pediatrics, Geriatrics, Pregnant Women) By Region (North America, Europe, APAC, South America, MEA) - Growth Outlook & Industry Forecast To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UTI Drugs Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Drug Type (USD Billion)
  49.     4.1.1 Antibiotics
  50.     4.1.2 Antiseptics
  51.     4.1.3 Analgesics
  52.     4.1.4 Antifungals
  53.   4.2 Healthcare, BY Administration Route (USD Billion)
  54.     4.2.1 Oral
  55.     4.2.2 Intravenous
  56.     4.2.3 Topical
  57.     4.2.4 Intramuscular
  58.   4.3 Healthcare, BY Patient Demographics (USD Billion)
  59.     4.3.1 Adults
  60.     4.3.2 Pediatrics
  61.     4.3.3 Geriatrics
  62.     4.3.4 Pregnant Women
  63.   4.4 Healthcare, BY Indication (USD Billion)
  64.     4.4.1 Uncomplicated Urinary Tract Infection
  65.     4.4.2 Complicated Urinary Tract Infection
  66.     4.4.3 Recurrent Urinary Tract Infection
  67.   4.5 Healthcare, BY Region (USD Billion)
  68.     4.5.1 North America
  69.       4.5.1.1 US
  70.       4.5.1.2 Canada
  71.     4.5.2 Europe
  72.       4.5.2.1 Germany
  73.       4.5.2.2 UK
  74.       4.5.2.3 France
  75.       4.5.2.4 Russia
  76.       4.5.2.5 Italy
  77.       4.5.2.6 Spain
  78.       4.5.2.7 Rest of Europe
  79.     4.5.3 APAC
  80.       4.5.3.1 China
  81.       4.5.3.2 India
  82.       4.5.3.3 Japan
  83.       4.5.3.4 South Korea
  84.       4.5.3.5 Malaysia
  85.       4.5.3.6 Thailand
  86.       4.5.3.7 Indonesia
  87.       4.5.3.8 Rest of APAC
  88.     4.5.4 South America
  89.       4.5.4.1 Brazil
  90.       4.5.4.2 Mexico
  91.       4.5.4.3 Argentina
  92.       4.5.4.4 Rest of South America
  93.     4.5.5 MEA
  94.       4.5.5.1 GCC Countries
  95.       4.5.5.2 South Africa
  96.       4.5.5.3 Rest of MEA
  97. 5 SECTION V: COMPETITIVE ANALYSIS
  98.   5.1 Competitive Landscape
  99.     5.1.1 Overview
  100.     5.1.2 Competitive Analysis
  101.     5.1.3 Market share Analysis
  102.     5.1.4 Major Growth Strategy in the Healthcare
  103.     5.1.5 Competitive Benchmarking
  104.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  105.     5.1.7 Key developments and growth strategies
  106.       5.1.7.1 New Product Launch/Service Deployment
  107.       5.1.7.2 Merger & Acquisitions
  108.       5.1.7.3 Joint Ventures
  109.     5.1.8 Major Players Financial Matrix
  110.       5.1.8.1 Sales and Operating Income
  111.       5.1.8.2 Major Players R&D Expenditure. 2023
  112.   5.2 Company Profiles
  113.     5.2.1 AstraZeneca (GB)
  114.       5.2.1.1 Financial Overview
  115.       5.2.1.2 Products Offered
  116.       5.2.1.3 Key Developments
  117.       5.2.1.4 SWOT Analysis
  118.       5.2.1.5 Key Strategies
  119.     5.2.2 Bristol-Myers Squibb (US)
  120.       5.2.2.1 Financial Overview
  121.       5.2.2.2 Products Offered
  122.       5.2.2.3 Key Developments
  123.       5.2.2.4 SWOT Analysis
  124.       5.2.2.5 Key Strategies
  125.     5.2.3 F. Hoffmann-La Roche (CH)
  126.       5.2.3.1 Financial Overview
  127.       5.2.3.2 Products Offered
  128.       5.2.3.3 Key Developments
  129.       5.2.3.4 SWOT Analysis
  130.       5.2.3.5 Key Strategies
  131.     5.2.4 Johnson & Johnson (US)
  132.       5.2.4.1 Financial Overview
  133.       5.2.4.2 Products Offered
  134.       5.2.4.3 Key Developments
  135.       5.2.4.4 SWOT Analysis
  136.       5.2.4.5 Key Strategies
  137.     5.2.5 Merck & Co. (US)
  138.       5.2.5.1 Financial Overview
  139.       5.2.5.2 Products Offered
  140.       5.2.5.3 Key Developments
  141.       5.2.5.4 SWOT Analysis
  142.       5.2.5.5 Key Strategies
  143.     5.2.6 Pfizer (US)
  144.       5.2.6.1 Financial Overview
  145.       5.2.6.2 Products Offered
  146.       5.2.6.3 Key Developments
  147.       5.2.6.4 SWOT Analysis
  148.       5.2.6.5 Key Strategies
  149.     5.2.7 Sanofi (FR)
  150.       5.2.7.1 Financial Overview
  151.       5.2.7.2 Products Offered
  152.       5.2.7.3 Key Developments
  153.       5.2.7.4 SWOT Analysis
  154.       5.2.7.5 Key Strategies
  155.     5.2.8 Teva Pharmaceutical Industries (IL)
  156.       5.2.8.1 Financial Overview
  157.       5.2.8.2 Products Offered
  158.       5.2.8.3 Key Developments
  159.       5.2.8.4 SWOT Analysis
  160.       5.2.8.5 Key Strategies
  161.   5.3 Appendix
  162.     5.3.1 References
  163.     5.3.2 Related Reports
  164. 6 LIST OF FIGURES
  165.   6.1 MARKET SYNOPSIS
  166.   6.2 NORTH AMERICA MARKET ANALYSIS
  167.   6.3 US MARKET ANALYSIS BY DRUG TYPE
  168.   6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
  169.   6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  170.   6.6 US MARKET ANALYSIS BY INDICATION
  171.   6.7 CANADA MARKET ANALYSIS BY DRUG TYPE
  172.   6.8 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  173.   6.9 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  174.   6.10 CANADA MARKET ANALYSIS BY INDICATION
  175.   6.11 EUROPE MARKET ANALYSIS
  176.   6.12 GERMANY MARKET ANALYSIS BY DRUG TYPE
  177.   6.13 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
  178.   6.14 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  179.   6.15 GERMANY MARKET ANALYSIS BY INDICATION
  180.   6.16 UK MARKET ANALYSIS BY DRUG TYPE
  181.   6.17 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
  182.   6.18 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  183.   6.19 UK MARKET ANALYSIS BY INDICATION
  184.   6.20 FRANCE MARKET ANALYSIS BY DRUG TYPE
  185.   6.21 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
  186.   6.22 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  187.   6.23 FRANCE MARKET ANALYSIS BY INDICATION
  188.   6.24 RUSSIA MARKET ANALYSIS BY DRUG TYPE
  189.   6.25 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  190.   6.26 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  191.   6.27 RUSSIA MARKET ANALYSIS BY INDICATION
  192.   6.28 ITALY MARKET ANALYSIS BY DRUG TYPE
  193.   6.29 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
  194.   6.30 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  195.   6.31 ITALY MARKET ANALYSIS BY INDICATION
  196.   6.32 SPAIN MARKET ANALYSIS BY DRUG TYPE
  197.   6.33 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
  198.   6.34 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  199.   6.35 SPAIN MARKET ANALYSIS BY INDICATION
  200.   6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG TYPE
  201.   6.37 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
  202.   6.38 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  203.   6.39 REST OF EUROPE MARKET ANALYSIS BY INDICATION
  204.   6.40 APAC MARKET ANALYSIS
  205.   6.41 CHINA MARKET ANALYSIS BY DRUG TYPE
  206.   6.42 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  207.   6.43 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  208.   6.44 CHINA MARKET ANALYSIS BY INDICATION
  209.   6.45 INDIA MARKET ANALYSIS BY DRUG TYPE
  210.   6.46 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  211.   6.47 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  212.   6.48 INDIA MARKET ANALYSIS BY INDICATION
  213.   6.49 JAPAN MARKET ANALYSIS BY DRUG TYPE
  214.   6.50 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
  215.   6.51 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  216.   6.52 JAPAN MARKET ANALYSIS BY INDICATION
  217.   6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG TYPE
  218.   6.54 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  219.   6.55 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  220.   6.56 SOUTH KOREA MARKET ANALYSIS BY INDICATION
  221.   6.57 MALAYSIA MARKET ANALYSIS BY DRUG TYPE
  222.   6.58 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  223.   6.59 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  224.   6.60 MALAYSIA MARKET ANALYSIS BY INDICATION
  225.   6.61 THAILAND MARKET ANALYSIS BY DRUG TYPE
  226.   6.62 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
  227.   6.63 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  228.   6.64 THAILAND MARKET ANALYSIS BY INDICATION
  229.   6.65 INDONESIA MARKET ANALYSIS BY DRUG TYPE
  230.   6.66 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  231.   6.67 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  232.   6.68 INDONESIA MARKET ANALYSIS BY INDICATION
  233.   6.69 REST OF APAC MARKET ANALYSIS BY DRUG TYPE
  234.   6.70 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
  235.   6.71 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  236.   6.72 REST OF APAC MARKET ANALYSIS BY INDICATION
  237.   6.73 SOUTH AMERICA MARKET ANALYSIS
  238.   6.74 BRAZIL MARKET ANALYSIS BY DRUG TYPE
  239.   6.75 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
  240.   6.76 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  241.   6.77 BRAZIL MARKET ANALYSIS BY INDICATION
  242.   6.78 MEXICO MARKET ANALYSIS BY DRUG TYPE
  243.   6.79 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
  244.   6.80 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  245.   6.81 MEXICO MARKET ANALYSIS BY INDICATION
  246.   6.82 ARGENTINA MARKET ANALYSIS BY DRUG TYPE
  247.   6.83 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  248.   6.84 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  249.   6.85 ARGENTINA MARKET ANALYSIS BY INDICATION
  250.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG TYPE
  251.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  252.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  253.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
  254.   6.90 MEA MARKET ANALYSIS
  255.   6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG TYPE
  256.   6.92 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
  257.   6.93 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  258.   6.94 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
  259.   6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG TYPE
  260.   6.96 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  261.   6.97 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  262.   6.98 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
  263.   6.99 REST OF MEA MARKET ANALYSIS BY DRUG TYPE
  264.   6.100 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  265.   6.101 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  266.   6.102 REST OF MEA MARKET ANALYSIS BY INDICATION
  267.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  268.   6.104 RESEARCH PROCESS OF MRFR
  269.   6.105 DRO ANALYSIS OF HEALTHCARE
  270.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  271.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  272.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  273.   6.109 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE)
  274.   6.110 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
  275.   6.111 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
  276.   6.112 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
  277.   6.113 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
  278.   6.114 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
  279.   6.115 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
  280.   6.116 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
  281.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  282. 7 LIST OF TABLES
  283.   7.1 LIST OF ASSUMPTIONS
  284.     7.1.1
  285.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  286.     7.2.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  287.     7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  288.     7.2.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  289.     7.2.4 BY INDICATION, 2025-2035 (USD Billion)
  290.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  291.     7.3.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  292.     7.3.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  293.     7.3.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  294.     7.3.4 BY INDICATION, 2025-2035 (USD Billion)
  295.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  296.     7.4.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  297.     7.4.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  298.     7.4.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  299.     7.4.4 BY INDICATION, 2025-2035 (USD Billion)
  300.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  301.     7.5.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  302.     7.5.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  303.     7.5.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  304.     7.5.4 BY INDICATION, 2025-2035 (USD Billion)
  305.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  306.     7.6.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  307.     7.6.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  308.     7.6.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  309.     7.6.4 BY INDICATION, 2025-2035 (USD Billion)
  310.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  311.     7.7.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  312.     7.7.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  313.     7.7.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  314.     7.7.4 BY INDICATION, 2025-2035 (USD Billion)
  315.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  316.     7.8.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  317.     7.8.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  318.     7.8.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  319.     7.8.4 BY INDICATION, 2025-2035 (USD Billion)
  320.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  321.     7.9.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  322.     7.9.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  323.     7.9.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  324.     7.9.4 BY INDICATION, 2025-2035 (USD Billion)
  325.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  326.     7.10.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  327.     7.10.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  328.     7.10.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  329.     7.10.4 BY INDICATION, 2025-2035 (USD Billion)
  330.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  331.     7.11.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  332.     7.11.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  333.     7.11.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  334.     7.11.4 BY INDICATION, 2025-2035 (USD Billion)
  335.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  336.     7.12.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  337.     7.12.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  338.     7.12.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  339.     7.12.4 BY INDICATION, 2025-2035 (USD Billion)
  340.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  341.     7.13.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  342.     7.13.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  343.     7.13.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  344.     7.13.4 BY INDICATION, 2025-2035 (USD Billion)
  345.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  346.     7.14.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  347.     7.14.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  348.     7.14.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  349.     7.14.4 BY INDICATION, 2025-2035 (USD Billion)
  350.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  351.     7.15.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  352.     7.15.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  353.     7.15.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  354.     7.15.4 BY INDICATION, 2025-2035 (USD Billion)
  355.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  356.     7.16.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  357.     7.16.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  358.     7.16.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  359.     7.16.4 BY INDICATION, 2025-2035 (USD Billion)
  360.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  361.     7.17.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  362.     7.17.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  363.     7.17.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  364.     7.17.4 BY INDICATION, 2025-2035 (USD Billion)
  365.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  366.     7.18.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  367.     7.18.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  368.     7.18.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  369.     7.18.4 BY INDICATION, 2025-2035 (USD Billion)
  370.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  371.     7.19.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  372.     7.19.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  373.     7.19.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  374.     7.19.4 BY INDICATION, 2025-2035 (USD Billion)
  375.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  376.     7.20.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  377.     7.20.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  378.     7.20.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  379.     7.20.4 BY INDICATION, 2025-2035 (USD Billion)
  380.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  381.     7.21.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  382.     7.21.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  383.     7.21.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  384.     7.21.4 BY INDICATION, 2025-2035 (USD Billion)
  385.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  386.     7.22.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  387.     7.22.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  388.     7.22.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  389.     7.22.4 BY INDICATION, 2025-2035 (USD Billion)
  390.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  391.     7.23.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  392.     7.23.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  393.     7.23.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  394.     7.23.4 BY INDICATION, 2025-2035 (USD Billion)
  395.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  396.     7.24.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  397.     7.24.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  398.     7.24.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  399.     7.24.4 BY INDICATION, 2025-2035 (USD Billion)
  400.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  401.     7.25.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  402.     7.25.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  403.     7.25.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  404.     7.25.4 BY INDICATION, 2025-2035 (USD Billion)
  405.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  406.     7.26.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  407.     7.26.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  408.     7.26.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  409.     7.26.4 BY INDICATION, 2025-2035 (USD Billion)
  410.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  411.     7.27.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  412.     7.27.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  413.     7.27.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  414.     7.27.4 BY INDICATION, 2025-2035 (USD Billion)
  415.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  416.     7.28.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  417.     7.28.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  418.     7.28.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  419.     7.28.4 BY INDICATION, 2025-2035 (USD Billion)
  420.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  421.     7.29.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  422.     7.29.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  423.     7.29.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  424.     7.29.4 BY INDICATION, 2025-2035 (USD Billion)
  425.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  426.     7.30.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  427.     7.30.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  428.     7.30.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
  429.     7.30.4 BY INDICATION, 2025-2035 (USD Billion)
  430.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  431.     7.31.1
  432.   7.32 ACQUISITION/PARTNERSHIP
  433.     7.32.1

Healthcare Market Segmentation

Healthcare By Drug Type (USD Billion, 2025-2035)

  • Antibiotics
  • Antiseptics
  • Analgesics
  • Antifungals

Healthcare By Administration Route (USD Billion, 2025-2035)

  • Oral
  • Intravenous
  • Topical
  • Intramuscular

Healthcare By Patient Demographics (USD Billion, 2025-2035)

  • Adults
  • Pediatrics
  • Geriatrics
  • Pregnant Women

Healthcare By Indication (USD Billion, 2025-2035)

  • Uncomplicated Urinary Tract Infection
  • Complicated Urinary Tract Infection
  • Recurrent Urinary Tract Infection

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions